Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 11/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 5/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 4/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 4/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 3/20 | 0.35 |
| ▸ | PRKDC | P78527 | 2/20 | 0.35 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 2/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177921 | 0.90 | ATR (0.39) | ATRACVRL1ACVR1BMPR1BBMPR1A | |
| SCHEMBL10231314 | 0.87 | ATR (0.65) | ATRATMPRKDCGSK3B | |
| SCHEMBL10177710 | 0.86 | ATR (0.53) | ATRACVRL1ACVR1BMPR1BBMPR1A | |
| SCHEMBL10177671 | 0.85 | ATR (0.45) | ATRACVRL1ACVR1BMPR1BBMPR1A | |
| SCHEMBL10177799 | 0.82 | ATR (0.46) | ATRACVRL1ACVR1BMPR1BBMPR1A | |
| SCHEMBL10177765 | 0.82 | ATR (0.55) | ATRACVRL1ACVR1BMPR1BBMPR1A | |
| SCHEMBL10177804 | 0.82 | ATR (0.40) | ATRACVRL1ACVR1BMPR1BBMPR1A | |
| SCHEMBL10177806 | 0.81 | ATR (0.42) | ATRACVRL1ACVR1BMPR1BBMPR1A | |
| SCHEMBL10177800 | 0.78 | ATR (0.45) | ATRATMPRKDCSOS1GSK3B | |
| SCHEMBL10177626 | 0.78 | ATR (0.58) | ATRACVRL1ACVR1BMPR1BBMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630956-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-25 | — | — | US | disclosed |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | ATR 1/4885ACVRL1 883/4885ACVR1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.